Myomo Inc
$ 0.78
7.22%
14 Apr - close price
- Market Cap 28,113,600 USD
- Current Price $ 0.78
- High / Low $ 0.78 / 0.73
- Stock P/E N/A
- Book Value 0.30
- EPS -0.37
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.86 %
- 52 Week High 4.99
- 52 Week Low 0.60
About
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$4.32
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-16 | 2025-11-10 | 2025-08-11 | 2025-05-06 | 2025-03-05 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-03-07 | 2023-11-07 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.0852 | -0.09 | -0.12 | -0.08 | -0.01 | -0.03 | -0.03 | -0.1 | -0.07 | -0.06 | -0.04 | -0.11 |
| Estimated EPS | -0.084 | -0.11 | -0.1 | -0.1 | -0.0233 | -0.04 | -0.07 | -0.1 | -0.06 | -0.09 | -0.03 | -0.13 |
| Surprise | -0.0012 | 0.02 | -0.02 | 0.02 | 0.0133 | 0.01 | 0.04 | 0 | -0.01 | 0.03 | -0.01 | 0.02 |
| Surprise Percentage | -1.4286% | 18.1818% | -20% | 20% | 57.0815% | 25% | 57.1429% | 0% | -16.6667% | 33.3333% | -33.3333% | 15.3846% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYO
2026-04-14 03:10:53
This page provides a comprehensive resource for Myomo SEC filings, including annual 10-K reports, quarterly 10-Q reports, and material event 8-K forms, offering investors detailed insights into the company's financial structure and operations. It highlights recent filings such as insider share purchases by the CEO, quarterly earnings reports, and disclosures regarding significant shareholdings by investment groups. The platform also offers AI-powered summaries and impact analysis for better understanding of these regulatory documents.
2026-04-13 20:10:53
This SEC filing ([144] Form 144) for MYOMO, INC. (MYO) details a proposed sale of securities, specifically common stock acquired through the vesting of restricted stock units. The filing indicates a sale of 3,953 shares with an aggregate market value of $2,806.60 on April 13, 2026, through broker Morgan Stanley. It also states there were no securities sold by this person in the past three months.
2026-04-12 18:09:32
Myomo Inc (MYO) reported strong Q3 2025 revenue of $10.1 million, despite a decrease in average selling price and gross margin. The company experienced record international revenues, particularly in Germany, and saw an increase in authorizations and orders due to new in-network contracts. However, increased operating expenses and a net loss of $3.7 million were noted, partly due to pre-authorization denials from Medicare Advantage payers.
2026-04-12 18:09:31
Myomo, Inc. (MYO) announced a fourth-quarter loss that was wider than anticipated but reported revenue that exceeded analyst expectations. The company posted a loss of $0.07 per share, while analysts had predicted a loss of $0.04 per share. However, Myomo's revenue reached $5.8 million, surpassing the estimated $5.6 million.
2026-04-12 03:39:09
Myomo, Inc. (MYO) reported a Q4 loss, but exceeded revenue estimates. This suggests that while profitability was a challenge, the company's sales performance was stronger than anticipated by analysts.
2026-04-01 01:40:46
The exoskeleton rehabilitation market is projected to reach $2.91 billion by 2030, growing at a CAGR of 17.4%, driven by technological advancements, home-based rehabilitation, AI-guided therapy, and an aging population. Key companies like Ottobock SE and Co KGaA, Fourier Intelligence, and Cyberdyne Inc. are leading this expansion, with significant strategic moves such as Bioness Medical Inc.'s acquisition of Harmonic Bionics Inc. The market is segmented by product type (lower, upper, full-body exoskeletons), mobility (mobile, stationary), application (neurological, orthopedic, spinal cord injury, stroke), and end-user (hospitals, rehabilitation centers).
